Endocarditis Infective
12
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
25%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Dalbavancin Therapy for Infective Endocarditis
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
Endocarditis Clinical Awareness, Research, and Evaluation in Sweden
Study of the Prognosis of Infectious Endocarditis (EPEI)
Transthoracic Echocardiography in Assessing Patients With Suspected Endocarditis
San Matteo Endocarditis Registry STEADY
The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
Prognosis and Management of Infective Endocarditis Using the Clinical Data Warehouse From AP-HP
Antibiotics Vs Antibiotics and Surgical ThERapy for Infective Endocarditis
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
Contemporary Transvenous Lead Extraction Outcomes